ListarInstituto de Investigación Biomédica da Coruña (INIBIC) por tema "Psoriatic arthritis"
Mostrando ítems 1-4 de 4
-
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
(BMJ, 2016-01-20)[Abstract] Objective. To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or ... -
Higher synovial immunohistochemistry reactivity of IL-17A, Dkk1, and TGF-β1 in patients with early psoriatic arthritis and rheumatoid arthritis could predict the use of biologics
(MDPI, 2024-04-08)[Abstract] Background: Delay in diagnosis and therapy in patients with arthritis commonly leads to progressive articular damage. The study aimed to investigate the immunohistochemical reactivity of synovial cytokines ... -
Increased synovial immunohistochemistry reactivity of TGF-β1 in erosive peripheral psoriatic arthritis
(BioMed Central, 2023-03-30)[Abstract] Background: Immune and non-immune cells contribute to the pathology of chronic arthritis, and they can contribute to tissue remodeling and repair as well as disease pathogenesis. The present research aimed to ... -
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
(Oxford University Press, 2014-12-19)[Abstract] Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations ...